Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo

NCT05430217 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT05430217
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05430217 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-blind Placebo-controlled Multicenter Randomized Clinical Trial to Evaluate the Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg (JSC Valenta Pharm, Russia) in Patients With Autonomic Dysfunction Syndrome Accompanied by Vertigo
Lead sponsor
Valenta Pharm JSC
Phase
Phase 3
Overall status
Completed
Start date
January 28, 2022
Completion date
May 9, 2022
Enrollment
268 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

autonomic dysfunction, vertigo